Exploit the Accelerating Technological Revolution
We have a tendency to focus on our everyday lives without truly appreciating how the world is changing around us. But understanding the tectonic shifts outside of our near-term consciousness is crucial to successful investing.
I realized the other day I’ve...
Read More
Traditional blue-chip multinational investments haven't produced great returns of late. To get a leg up, consider these two emerging market alternatives.
Read More
The market remains strong and I continue to recommend that you be heavily invested in a well-diversified portfolio that meets your investment needs.
Read More
It's not entirely unusual for a new CEO at a company to change the dividend policy due to having a different idea of how the company should be using its cash flow.
Read More
From Cabot Top Ten Trader
It’s fair to say the broad buying pressures have eased up, though to this point, the sellers haven’t done much damage at all. We’re going along with the back-and-forth action, nudging our Market Monitor down a notch—we remain overall but...
Read More
The ETF has a current annual dividend yield of 3.54%, paid semi-annually.
Read More
Two stocks are moving up and a third stock is moving from Buy to Strong Buy.
Read More
Stock Recommendation Tracker
By request, we have added a new feature to your Cabot Prime Weekly Summary—the Stock Recommendation Tracker. It is a table that features all of the current recommendations in all of our portfolios. It’s a quick way for you to see stocks...
Read More
Stock Recommendation Tracker
By request, we have added a new feature to your Cabot Prime Weekly Summary—the Stock Recommendation Tracker. It is a table that features all of the current recommendations in all of our portfolios. It’s a quick way for you to see stocks...
Read More
Prepare yourself for more ups and downs in our medtech & biotech stocks if this debate heats up. I’m not planning to step out of the space since I think this will pass and we can still do quite well with these types stocks.
...
Read More
The overall market remains in good shape, with both of our trend-following indicators—the Cabot Tides (intermediate-term) and Cabot Trend Lines (longer-term)—currently pointing up. We’re still keeping an eye on small-cap indexes, which have still not eclipsed their late February peaks, as well as Nasdaq,...
Read More
Our Emerging Markets Timer is still solidly in the bull camp, with the recent pullback being modest compared to the year-to-date upmove.
Read More
Crista has several portfolio updates and changes today.
Read More
This long-term bond ETF has just hit its buy price.
Read More
The new all time high is a significant milestone. Although the S&P 500 hasn’t hit new highs quite yet it is only just about .01% from the mark. The new high is significant because it negates any possibility that we have been in bear...
Read More
After dipping as low as $42, crude oil prices are back near $59 a barrel. These three oil ETFs are an efficient way to play the latest energy mini-rally.
Read More
The market remains strong and I continue to recommend that you be heavily invested in a well-diversified portfolio that meets your investment needs.
Read More
The current annual dividend yield on this closed-end fund is 9.4%, paid quarterly.
Read More
The top five holdings of this Morningstar three-star-rated fund are: BioTelemetry Inc (BEAT, 4.78% of assets); Vericel Corp (VCEL, 4.64%); CareDx Inc (CDNA, 4.43%); Fluidigm Corp (FLDM, 4.14%); and AtriCure Inc (ATRC, 4.08%).
Read More
A good way to invest in global growth is to own real estate in different parts of the world. And global REITs are a hassle-free way to do it.
Read More
